$PVSP 24 Months plan detail
Rename Pervasip Corp to Artizen Corporation by year end 2022 to better reflect the new focus of the company
Change the OTC ticker symbol
Re-brand all Pervasip/Artizen assets
Continue to rationalize the business through Q1 2023 with a focus on operating margins, shedding underperforming assets, consolidating operations and focus in-house talent on higher margin operations and product lines
Acquire concentrates assets by end of 2022, launching into the highly lucrative concentrates business
Expand flower and concentrates offerings within our brands as well as adding new brands for certain product offerings and price points through Q1 2023
Complete the audit and begin the OTC QB application process during Q2 2023
Launch Artizen Wellness Q2 2023
Enter the edibles market in Q2 2023 via acquisition and partnerships
Artizen becomes an MSO with cultivation and retail assets in 1 – 2 additional states during 2nd half of 2024, beginning its state expansion in Q1 2023, initially through brand licensing opportunities and strategic partnerships, and eventually via acquisitions and mergers during Q3 and Q4 2024
Close first brand licensing agreement by end of Q4 2022
Close one brand licensing deal every quarter thereafter
Financial Outlook Q3 2022 through Q4 2023
Reach $2.0 million in monthly revenue by end of Q1 2023
Reach $2.5 million or $30 million in annualized revenue by end of Q4 2023 with 30% in adjusted EBIDTA
Reach $3.0 million or $36 million in annualized revenues by end of Q2 2024 with 35% in adjusted EBIDTA
Reach $50 million in annualized revenue with 35% in adjusted EBIDTA
AI
